Drew Taylor from Acorn Biolabs

Drew Taylor is the Co-Founder and CEO of Acorn Biolabs.

Acorn has developed the world’s first non-invasive, follicle-based cell cryopreservation service and has patented cell-based treatments made from a patient’s own hair follicle cells.

Takeaways

Moving from playing MLB baseball to doing his PhD.

Regenerative medicine is needed to address the limitations of prosthetics and improve patient outcomes.

Banking younger cells can provide better results in regenerative medicine and enhance healthspan.

The field of regenerative medicine is gaining momentum, with a focus on anti-aging, longevity, and healthspan.

Raising capital in the regenerative medicine space can be challenging due to the complexity of the field and the need to find investors who understand both the medical and business aspects.

Acorn's banking service involves specialized facilities for processing and storing cells, leveraging existing infrastructure, and ensuring safety and maintenance.

The future of regenerative medicine includes making the storage of younger cells a standard of care and leveraging stem cells for maintenance and performance as individuals age.

Chapters

00:00 Transition from Baseball to PhD

01:35 Lessons from Baseball for Founding a Company

07:06 Identifying the Need for Regenerative Medicine

09:25 The Importance of Collecting Younger Cells

12:17 Driving Factors in the Regenerative Medicine Space

20:17 Team Composition at Acorn

23:38 Raising Capital in the Regenerative Medicine Space

28:03 Acorn's Banking Service and Expansion

30:57 The Future of Acorn and Regenerative Medicine

35:21 Dealing with Hard Times

37:02 Engaging with Regenerative Medicine